AFFILIATIONS
1 Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
2 Ottawa Hospital Research Institute, Ottawa, Ontario, Canada, University of Ottawa, Ottawa, Ontario, Canada
ABSTRACT
Background:
Hemophilia is classified as mild, moderate, or severe according to endogenous factor VIII or IX activity (5–40%, 1–5%, and <1%, respectively). However, factor activity does not consistently predict bleeding, functional impact, treatment requirements, or patient experience. Although bleeding phenotype is increasingly recognized, it remains inconsistently defined and applied. We examined how multidisciplinary clinicians at hemophilia treatment centers (HTCs) conceptualize, use, and adapt the classification system and what they believe a revised framework should include.
Methods:
We conducted a constructivist grounded theory study using semi-structured interviews with HTC clinicians purposively recruited through Canadian hemophilia organizations and snowball sampling. Data collection and analysis proceeded iteratively using constant comparison, initial, focused, and theoretical coding, team discussion, and reflexive memo writing.
Results:
Nineteen clinicians working in adult, pediatric, or lifespan hemophilia care participated: 7 physicians, 5 nurses or nurse practitioners, 5 physiotherapists, and 2 pharmacists. The core category, repairing a biologically anchored classification through contextual clinical reasoning, explained how clinicians retained factor activity as a starting point while continually revising its clinical meaning through three interrelated theoretical categories.
First, factor-level categories were viewed as inadequate, potentially misleading, and inequitable when used alone. Factor activity remained useful for anticipating untreated risk, particularly in newly diagnosed children and people with severe deficiency, but moderate hemophilia was unpredictable and the mild category encompassed widely divergent bleeding experiences. Assay discordance could change category assignment, while women and people labelled carriers were particularly vulnerable to underrecognition. Participants reported that patients and non-HTC clinicians often interpreted mild, moderate, severe, and carrier as descriptions of the whole illness rather than laboratory classifications. They linked these interpretations to delayed emergency and peri-procedural care and barriers to prophylaxis and newer therapies.
Second, clinicians repaired these limitations by “treating the patient in front of them.” They integrated bleeding history and location, treatment response, family history, age, activity, joint and functional health, comorbidities, quality of life, and patient goals. This reasoning shaped surveillance, prophylaxis, documentation, and funding advocacy. Adaptations included describing “moderate hemophilia with a severe bleeding phenotype,” expanding bleeding histories in clinic letters, using electronic alerts and individualized care plans, and, in some centers, removing mild or moderate from emergency cards. However, these adaptations were informal, inconsistent, and often lost or misunderstood outside HTCs.
Third, participants proposed alternative frameworks without reaching consensus. Most favored retaining factor activity while adding a standardized, dynamic descriptor of bleeding phenotype or illness impact. Proposed dimensions included bleeding pattern, treatment requirements, joint and functional health, quality of life, life stage, activity, psychosocial effects, and patient-reported outcomes. Other options included removing severity labels, revising numerical cutoffs, or distinguishing prophylaxis-requiring from non-prophylaxis-requiring hemophilia. Participants cautioned that complex frameworks would have limited uptake and that treatment-based categories could reproduce inequities where access differs.
Conclusion:
Clinicians used the current classification as a biological anchor rather than a complete representation of hemophilia severity. HTCs compensated through longitudinal, multidisciplinary, and contextual reasoning, but this reasoning was poorly transferred to non-specialist care, funding, and research systems. A revised classification should pair factor activity with a concise, standardized, and revisable biopsychosocial description of bleeding expression and illness impact. Future work should co-develop and test this framework with patients, clinicians, researchers, funders, and non-specialist healthcare professionals.
DISCLOSURES
Roy Khalife, MD, MHPE: Bayer - Honoraria; Roche - Honoraria; Pfizer - Honoraria; Medecins Francophones du Canada - Honoraria; Sanofi - Honoraria; Novo Nordisk - Honoraria; Sobi - Honoraria; Novartis - Honoraria; Canadian Drug Agency - Honoraria; Takeda - Honoraria; CSL Behring - Honoraria; Octapharma - Honoraria